

Subject: Medical Science Liaison (MSL) Notes - Introduction of NeuroSolvix

Date: February 20, 2025

Provider: Dr. Emily Harper

Title: Neurologist

Institution: BrainHealth Neurological Center

Summary of Key Discussion Points:

1. Introduction:

- Introduced NeuroSolvix as a potential breakthrough therapy for the management of neurodegenerative diseases.
- Emphasized its unique mechanism targeting synaptic plasticity and neuroinflammation.

2. Provider's Current Patient Cases:

- Dr. Harper expressed interest in innovative approaches for patients with progressive neurodegenerative conditions.
- Discussed specific cases where current neuroprotective therapies have shown limited efficacy or lack of disease-modifying effects.

3. Efficacy and Clinical Data:

- Presented recent clinical data showcasing NeuroSolvix's ability to slow disease progression by 30% and improve cognitive function in Alzheimer's patients.
- Highlighted statistically significant improvements in biomarkers associated with synaptic health.

4. Safety Profile:

- Discussed the favorable safety profile of NeuroSolvix, with minimal reported adverse effects.
- Dr. Harper inquired about potential interactions with commonly prescribed neurological medications.

5. Mechanism of Action:

- Explained NeuroSolvix's mechanism, focusing on its role in enhancing synaptic resilience and reducing neuroinflammation.
- Dr. Harper appreciated the drug's novel approach and sought insights into its potential for long-term neuroprotection.

6. Patient Adherence and Education:

- Discussed strategies for enhancing patient adherence through a once-monthly intravenous infusion.
- Shared patient education materials emphasizing the importance of early intervention for sustained neuroprotection.

7. Emerging Research and Future Developments:

- Highlighted ongoing research on NeuroSolvix's potential in other neurodegenerative conditions, such as Parkinson's disease.
- Discussed plans for exploring combination therapies to address multifactorial aspects of neurodegeneration.

8. Competitive Landscape:

- Compared NeuroSolvix to existing neuroprotective therapies, emphasizing its unique mechanism and potential for comprehensive neuroprotection.
- Discussed the need for personalized treatment plans considering the diverse nature of neurodegenerative diseases.

9. Access and Reimbursement:

- Provided updates on access and reimbursement programs for neurological clinics.
- Discussed potential affordability concerns and patient assistance programs.

10. Action Items and Follow-Up:

- Dr. Harper expressed interest in considering NeuroSolvix for ongoing clinical trials in her patient population.
- Agreed upon a follow-up in three months to provide additional data and address any ongoing concerns.

11. Closing Remarks:

- Expressed gratitude for Dr. Harper's dedication to advancing neurological care.
- Reiterated commitment to ongoing collaboration and support for the BrainHealth Neurological Center.